Dispensing Study for a New Study Lens

NCT ID: NCT02642991

Last Updated: 2020-12-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-30

Study Completion Date

2016-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigated the performance criteria over one week of daily wear to determine if the comfilcon A asphere lens (test) performed equivalently to the comfilcon A sphere (control) in terms of measurement and subjective ratings of visual performance.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study was a prospective, single site, daily wear, double masked, randomized bilateral cross over dispensing study of binocular wear of comfilcon A asphere lens (test) and comfilcon A sphere lens (control) over 1 week of daily wear.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Phenacite Test lens then comfilcon A control lens

Participants were randomized to wear Phenacite test lens for one week then cross-over to wear comfilcon A control lens for one week.

Group Type EXPERIMENTAL

Phenacite

Intervention Type DEVICE

contact lens

comfilcon A

Intervention Type DEVICE

contact lens

Comfilcon A control lens then Phenacite test Lens

Participants were randomized to wear comfilcon A control lens for one week then cross over to Phenacite test lens for one week.

Group Type ACTIVE_COMPARATOR

Phenacite

Intervention Type DEVICE

contact lens

comfilcon A

Intervention Type DEVICE

contact lens

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Phenacite

contact lens

Intervention Type DEVICE

comfilcon A

contact lens

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

A person is eligible for inclusion in the study if he/she:

* Oculo-visual examination in the last two years
* Between 18 and 35 years of age and has full legal capacity to volunteer
* Has read and understood the informed consent letter
* Is willing and able to follow instructions and maintain the appointment schedule
* Is correctable to a visual acuity of 20/25 or better (in each eye) with their habitual correction or 20/20 best corrected
* Currently wears, or has previously successfully worn, soft contact lenses between -1.00D (Diopoter) and -4.00D
* Spherical Contact Lens Rx between -1.00 and -4.00 and spectacle cylinder \<-0.75
* Has not worn lenses for at least 12 hours before the initial visit
* Has a subjective response at baseline, which indicates suitability for this study
* Currently spends a minimum of 4 hours a day; 5 days a week on digital devices and can replicate this time during the study period
* Is willing and able to wear the study contact lenses a minimum of 10 hours per day; 5 days a week

Exclusion Criteria

A person will be excluded from the study if he/she:

* Has never worn contact lenses before
* Any systemic disease affecting ocular health
* Is using any systemic or topical medications that will affect ocular health
* Has known sensitivity to the diagnostic pharmaceuticals or study products used in this study.
* Has any ocular pathology or anomaly that would affect the wearing of the lenses
* Has persistent, clinically significant corneal or conjunctival staining using sodium fluorescein dye
* Is aphakic
* Has anisometropia of \>1.00
* Has undergone corneal refractive surgery
* Has strabismus
* Has any ocular amblyopia \>= 1line of HC (High Contrast) Visual Acuity
* Is participating in any other type of eye related clinical or research study
* Has previously participated in study of the Phenacite lenses
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CooperVision, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lyndon Jones

Role: PRINCIPAL_INVESTIGATOR

CCLR, University of Waterloo

Pete Kollbaum, OD, PhD

Role: PRINCIPAL_INVESTIGATOR

CORL, Indiana University

Meng Lin, OD, PhD

Role: PRINCIPAL_INVESTIGATOR

CRC, University of California, Berkeley

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California

Berkeley, California, United States

Site Status

CORL, Indiana University

Bloomington, Indiana, United States

Site Status

Center for Contact Lens Research, University of Waterloo

Waterloo, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CV-15-41

Identifier Type: -

Identifier Source: org_study_id

NCT02642341

Identifier Type: -

Identifier Source: nct_alias

NCT02642354

Identifier Type: -

Identifier Source: nct_alias